PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40043848,Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy.,2025-03-03,Wang Guoqing; Marinello Patricia; Chakraborty Samhita; Orlowski Robert,"Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey.",john.kuruvilla@uhn.ca
40042109,"Melanoma Cell Adhesion Molecule Plays a Pivotal Role in Proliferation, Migration, Tumor Immune Microenvironment, and Immunotherapy in Colorectal Cancer.",2025-03-01,Lai Jun,"The Infirmary of Hangzhou Power Supply Company of State Grid, Zhejiang Electric Power Co., Ltd, Hangzhou, China.",
40042035,Mitigating Cellular Dysfunction Through Contaminant Reduction in Synthetic circRNA for High-Efficiency mRNA-Based Cell Reprogramming.,2025-03-05,Wang Daming,"BiosynRNA Biotechnology Company, Haidian District, Beijing, 100192, China.",
40032717,Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes.,2025-03-03,Li Ran; Grosskopf Abigail K; Joslyn Louis R; Stefanich Eric Gary; Shivva Vittal,"Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, 1 DNA Way, South San Francisco, California, 94080, USA.; Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, 1 DNA Way, South San Francisco, California, 94080, USA. li.ran@gene.com.; Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, 1 DNA Way, South San Francisco, California, 94080, USA. shivvav@gene.com.",li.ran@gene.com
40021461,"Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.",2025-03-01,Kilgore Karl M; Chan Philip K; Teigland Christie; Mohammadi Iman,"Inovalon, Inc., Bowie, MD.",
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025-02-24,Thomas Steven; Aksyuk Anastasia A; Currie Alexander; Flyrin Karin; Gibbs Michael; Perez John L; Chang Lee-Jah; Cohen Taylor S,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, MÃ¶lndal, Sweden.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.; Biometrics, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA.; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com.",haidarg@upmc.edu
